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(57) ABSTRACT
Disclosed is a method of stimulating cartilage growth, repair
or regeneration at a site in a subject in need of such growth,
repair or regeneration. The method comprises the step of
administering a therapeutically effective amount of an ago-
nist of the non-proteolytically activated thrombin receptor to
the site.
Also disclosed is a method of stimulating the proliferation
and expansion of chrondrocytes in vitro. The method com-
prises culturing chrondrocytes in the presence of a stimu-
lating amount of an NPAR agonist.





Nadir, M., et al., “Inhibition of coronary restenosis by
antithrombin III in atherosclerotic swine,” Coronary Artery
Disease, 7(11):851-861, (1996).
Munro, E., et al., “Inhibition of human vascular smooth
muscle cell proliferation by lovastatin: the role of isoprenoid
intermediates of cholesterol synthesis,” EuropeanJournal of
Clinical Investigation, 24(11):766-772, (1994).
Chen, S.J., et al., “Mithramycin Inhibits Myointimal Prolif-
eration After Balloon Injury of the Rat Carotid Artery In
Vivo,” Circulation, 90(5):2468-2473, (1994).
Shi, Y., et al., “Downregulation of c-myc Expression by
Antisense Oligonucleotides Inhibits Proliferation of Human
Smooth Muscle Cells,” Circulation, 88(3):1190-1195,
(1993).
Speir, E., and Epstein, S.E., “Inhibition of Smooth Muscle
Cell Proliferation by an Antisense Oligodeoxynucleotide
Targeting the Messenger RNA Encoding Proliferating Cell
Nuclear Antigen,” Circulation, 86(2):538-547, (1992).
Stiernberg, J., et al., “The Role of Thrombin and Thrombin
Receptor Activating Peptide (TRAP-508) in Initiation of
Tissue —_Repair,” Thrombosis and Haemostasis,
70(1):158-162, (1995).
Carey, D.H., et al., “Enhancement of Incisional Wound
Healing and Neovascularization in Normal Rats by Throm-
bin and Synthetic Thrombin Receptor—activating Peptides,”
J. Clin. Invest., 89:1469-1477, (1992).
Camey, D.H., et al. “Role of High—Affinity Thrombin
Receptors in Postclotting Cellular Effects of Thrombin,”
Seminars in Thrombosis and Hemostasis, 18(1):91-102,
(1992).
Stiernberg, J., et al., “Acceleration of full-thickness wound
healing in normal rats by the synthetic thrombin peptide,
TP508,” Wound Repair and Regeneration, 8(3):204-215,
(2000).
Glenn, K.C., et al., “Synthetic Peptides Bind to High—Affin-
ity Thrombin Receptors and Modulate Thrombin Mitogen-
esis,” Peptide Research, 1(2):65—73, (1988).
Sower, L.E., et al., “Thrombin Peptide, TP508, Induces
Differential Gene Expression in Fibroblasts through a Non-
proteolytic Activation Pathway,” Experimental Cell
Research, 247-422-431, (1999).
Carey, D.H., “Postclotting Cellular Effects of Thrombin
Mediated by Interaction with High—Affinity Thrombin
Receptors,” Thrombin: Structure and Function, Chapter 10,
pp. 351-396, (1992).
O’Connor, W.J., et al., “The Use of Growth Factors in
Cartilage Repair,” Orthopedic Clinics of North America,
31(3): 399-409 (2000).
Frenkel, S.R., et al., “Transforming Growth Factor Beta
Superfamily Members: Role in Cartilage Modeling,” Plastic
and Reconstructive Surgery, 105(3): 980-990 (2000).
Sellers, R.S., et al., “Repair of Articular Cartilage Defects
One Year After Treatment with Recombinant Human Bone
Morphogenetic Protein—2 (rhBMP-2),” J. of Bone & Joint
Surgery, 82(2): 151-160 (2000).
Sanyal, A., et al., “Initial Evidence for the Involvement of
Bone Morphogenetic Protein—2 Early during Periosteal
Chondrogenesis,” J. of Orthopaedic Research, 17(6):
926-934 (1999).
Louwerse, R.T., et al., “Use of Recombinant Human Osteo-
genic Protein—1 for the Repair of Subchondral Defects in
Articular Cartilage in Goats,” J. of Biomedical Materials
Res., 49(4): 506-516 (2000).
Nixon, A.J., et al., “Enhanced Repair of Extensive Articular
Defects by Insulin-Like Growth Factor-I-Laden Fibrin
Composites,” J. of Orthopaedic Res., 17:475—-487 (1999).
Fujimoto, E., et al., “Beneficial Effect of Basic Fibroblast
Growth Factor on the Repair of Full-Thickness Defects in
Rabbit Articular Cartilage,” Archives of Orthopaedic and
Trauma Surgery, 119(3-4): 139-145 (1999).
Koepp, H.E., et al., “Osteogenic Protein—1(OP-1) Blocks
Cartilage Damage Caused by Fibronectin Fragments and
Promotes Repair by Enhancing Proteoglycan Synthesis,”
Inflammation Res., 48(4): 199-204 (1999).
Hogervorst, T., et al. “The Effect of a TCP-Collagen
Implant on the Healing of Articular Cartilage Defects in the
Rabbit Knee Joint,” J. ofApplied Biomaterials, 3:251-258
(1992).
Reddi, A.H., “Cartilage-Derived Morphogenetic Proteins
and Cartilage Morphogenesis,” Microscopy Res. & Tech-
nique, 43(2): 131-136 (1998).
Nishida, Y., et al., “Osteogenic proten—1 promotes the syn-
thesis and retention of extracellular matrix within bovine
articular cartilage and chondrocyte cultures,” Osteoarthritis
and Cartilage, 8: 127-136 (2000).
Crowther, R.S., et al., “Thrombin Peptide TP508 Signifi-
cantly Accelerates Repair of Fresh Fractures,” Distributed at
Texas Mineralized Tissue Society, Austin, Texas. Aug. 1998.
Simmons, D.J., et al., “Acceleration of Rat Femoral Fracture
Healing by a Synthetic Thrombin Peptide,’ Calcium
Metabolism: Comparative Endocrinology. Proc Satellite
Meeting, San Francisco, CA. Nov. 30, 1998. (Eds. C. Dacke,
J. Danks, G. Flik and C. Gay). BioScientifica Ltd. Bradley
Stoke, Bristol, UK. 1999.
Yanget al., “Accelerated Repair of Segmental Defects by a
Synthetic Thrombin Peptide,” Handout that was distributed
at the Texas Mineralized Tissue Society Meeting, Sep. 1999.
Press Release —Orthologic Licenses Worldwide Orthopedic
Soft Tissue Rights For Chrysalin, Jul. 9, 2001).
* cited by examiner
US 6,855,687 B2
1
STIMULATION OF CARTILAGE GROWTH




This application is a continuation-in-part of U.S. appli-
cation Ser. No. 09/909,348 filed Jul. 19, 2001, which claims
the benefit of U.S. Provisional Application No. 60/219,800.
filed Jul. 20, 2000, the entire teachings of which are incor-
porated herein by reference.
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BACKGROUND OF THE INVENTION
Unlike most tissues, cartilage does not self-repair follow-
ing injury. Cartilage is an avascular tissue made up largely
of cartilage specific cells, the chondrocytes, special types of
collagen, and proteoglycans. The inability of cartilage to
self-repair after injury, disease, or surgery is a major limiting
factor in rehabilitation of degrading joint surfaces and injury
to meniscal cartilage. Osteoarthritis, the major degenerative
disease of weight bearing joint surfaces, is caused by erod-
ing or damagedcartilage surfaces and is present in approxi-
mately 25% of the over 50-year-old population. In the US
more than 20 million people suffer from osteoarthritis, with
annual healthcare costs of more than $8.6 billion. In
addition, the cost for cartilage repair from acute joint injury
(meniscal lesions, patellar surface damage and
chondromalacia) exceeds $1 billion annually. Therefore,
new therapeutic approaches are needed to heal lesions of
cartilage caused by degeneration or acute trauma.
SUMMARYOF THE INVENTION
It has now been found that chondrocytes isolated from
articular cartilage respond to compounds whichactivate the
non-proteolytic thrombin cell surface receptor (hereinafter
“NPAR”). For example, chondrocytes express approxi-
mately 233,000 thrombin binding sites per cell with appar-
ent affinities of approximately 0.1 nM (3000 sites) and 27
oM (230,000 sites) (Example 1). In addition, the compound
TP508, an agonist of the non-proteolytic thrombin receptor,
stimulates proliferation of bovine chondrocytes in culture in
the presence of thrombin as a co-mitogen (Example 2A) and
stimulates by itself the proliferation of rat chondrocytes
cultured in three dimensional matrix culture (Example 3A).
This same TP508 compound also stimulates proteoglycan
synthesis as measured by the incorporation of *°S sulfate in
both bovine chondrocytes (Example 2B) and 3-dimensional
cultures of rat chondrocytes (Example 3B). These in vitro
experiments demonstrate that NPAR agonists can stimulate
proliferation and matrix production in chondrocytes isolated
from articular cartilage. Additional in vivo experiments
demonstrate that delivering TP508 in a sustained release
formulation to rabbit trochlear grove cartilage defects which
extend into the subchondral bone results in repair of the
cartilage defect, including repair of subchondral bone,res-
toration of a normal cartilage surface and integration of the
newly formed cartilage with uninjured cartilage outside of














Basedonthe results reported in the prior paragraph, novel
methods of stimulating chondrocyte growth in vivo and
cartilage repair in a subject and novel delivery methods for
delivering pharmaceutical compositions to articular defects
to aid in surface repair and to prevent articular degradation
are disclosed herein.
The present invention is a method of stimulating cartilage
growth, regeneration or repair at a site in a subject where
cartilage growth, repair or regeneration is needed. The
method comprises the step of administering a therapeutically
effective amount of an agonist of the non-proteolytically
activated thrombin receptor to the site of injury.
Another embodimentof the present invention is a method
of stimulating the proliferation and expansion of chrondro-
cytes in vitro. The method comprises culturing chrondro-
cytes in the presence of a stimulating amount of an NPAR
agonist.
DETAILED DESCRIPTION OF THE
INVENTION
Sites in need of cartilage growth, repair or regeneration
are found in subjects with osteoarthritis. Osteoarthritis or
degenerative joint disease is a slowly progressive,
irreversible, often monoarticular disease characterized by
pain and loss of function. The underlying cause of the pain
and debilitationis the cartilage degradation that is one of the
major symptoms of the disease. Hyaline cartilage is a
flexible tissue that covers the ends of bones andlies between
joints such as the knee. It is also found in between the bones
along the spine. Cartilage is smooth, allowing stable, flex-
ible movement with minimal friction, but is also resistant to
compression and able to distribute applied loads. As osteoar-
thritis progresses, surfaces of cartilage and exposed under-
lying bone becomeirregular. Instead of gliding smoothly,
boney joint surfaces rub against each other, resulting in
stiffness and pain. Regeneration of damaged cartilage and
the growth of new cartilage at these arthritic sites would
relieve the pain and restore the loss of function associated
with osteoarthritis.
Cartilage damage can also occur from traumaresulting
from injury or surgery. Sports injuries are a common cause
of cartilage damage, particularly to joints such as the knee.
Traumatic injury to cartilage can result in the same type of
functional impairment. Therefore, sites in a subject with
cartilage that has been damaged by traumaor disease are in
need of treatment to restore or promote the growth of
cartilage.
Applicants have discovered that compounds which stimu-
late or activate the non-proteolytically activated thrombin
receptor (hereinafter “NPAR”) can stimulate chondrocytes
to proliferate. Chondrocytes are cells which make up about
1% of the volume of cartilage and which replace degraded
matrix molecules to maintain the correct volume and
mechanical properties of the tissue. Applicants have also
found that compounds which stimulate or activate NPAR
stimulate proteoglycan synthesis in chondrocytes. Pro-
teoglycan is a major cartilage component. Based on these
results, Applicants delivered the NPAR agonist TP508,
prepared in a sustained release formulation, to defects in
rabbit trochlear grove cartilage and discovered that the
peptide stimulated repair of the defect that included forma-
tion of new cartilage with a normal cartilage surface. The
peptide also stimulated layering and integration of this new
cartilage into adjacent, uninjured cartilage and restoration of
the subchondral bone.It is concluded that NPAR agonists
can induce cartilage growth and repair when administered to
sites needing cartilage growth and/or repair.
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Compounds whichstimulate or activate NPAR are said to
be NPAR agonists. NPAR is a high-affinity thrombin recep-
tor present on the surface of most cells. NPAR is largely
responsible for high-affinity binding of thrombin,proteolyti-
cally inactivated thrombin, and thrombin derived peptides to
cells. NPAR agonists and antagonists can compete for the
affinity binding with thrombin to cells (see, e.g., Glenn et al.,
J. Peptide Research 1:65 (1988)). NPAR appears to mediate
a numberof cellular signals that are initiated by thrombin
independent of its proteolytic activity. An example of one
such signal is the upregulation of annexin V and other
molecules identified by subtractive hybridization (see
Sower,et. al., Experimental Cell Research 247:422 (1999)).
NPAR is therefore characterized by its high affinity interac-
tion with thrombin at cell surfaces and its activation by
proteolytically inactive derivatives of thrombin and throm-
bin derived peptide agonists as described below. NPAR
activation can be assayed based onthe ability of its agonists
to stimulate cell proliferation when added to fibroblasts in
the presence of submitogenic concentrations of thrombin or
molecules that activate protein kinase C as disclosed in U.S.
Pat. Nos. 5,352,664 and 5,500,412.
NPAR isto be distinguished from other thrombin binding
proteins and the cloned family of proteolytically-activated
receptors for thrombin, including the receptors PAR1,
PAR2, PAR3 and PAR4. PAR1 possesses a specific thrombin
cleavagesite that allows thrombin cleavage to expose a new
amino-terminus domainthat acts as a tethered ligand folding
back onto itself inducing its activation (see, Vu,et al., Cell.
64:1057 (1991)). PAR2 has a similar mechanism for
activation, but is principally activated by trypsin-like
enzymes (see, Zhong, et al., J. Biol. Chem. 267:16975
(1992)). PAR3 also has a similar mechanism of activation
and appears to function as a second thrombin receptor in
platelets (see, Ishihara, et al., Nature. 386:502 (1997)).
PAR4 has been detected in mouse megakaryocytes and
studies suggest that it also functions in humanplatelets (see,
Kahn,et al., Nature 394:690 (1998)). In contrast with these
PAR receptors, activation of NPAR requires no proteolytic
cleavage.
Several lines of evidence indicate that NPAR is distinct
from PAR receptors: (1) a population of cells has been
isolated that express fully functional PAR1 receptors, but are
non-responsive to thrombin due to a defect in the NPAR
signal transduction pathway (see, Kim, et al. J. Cell.
Physiol. 160:573 (1994)); (2) neutrophils bind **°T thrombin
with high affinity and their chemotaxis is stimulated by
proteolytically inactivated thrombin or NPAR agonists(see,
Ramakrishnan and Cammey, Mol. Biol. Cell 4:1993 (1993)),
yet they do not express PAR1(see Jenkins,etal., J. Cell Sci.
108:3059 (1995)); (3) IIC9 fibroblasts over-express PAR1,
but do not bind thrombin with high affinity (see, Kim, D.
Ph.D. Dissertation. The University of Texas Medical Branch
at Galveston, 1995; and Low,et al., “Cancer Cells 3/Growth
Factors and Transformation”, Cold Spring Harbor
Laboratory, New York); and (4) NPAR agonists havedistinct
effects on gene expression from those of the PAR receptor
agonist peptides (see, Sower, et. al., Experimental Cell
Research 247: 422 (1999).
One example of an NPAR agonist is a thrombin peptide
derivative and physiologically functional equivalents.i.e., a
polypeptide with no more than about fifty amino acids,
preferably no more than about thirty amino acids and having
sufficient homology to the fragment of human thrombin
corresponding to prothrombin amino acids 508-530 (SEQ
ID NO:5)that the polypeptide activates NPAR. The throm-














between about 12 and 23 amino acids, more preferably
between about 19 and 23 amino acids. One example of a
thrombin peptide derivative comprises a moiety represented
by Structural formula (1):
Asp-Ala-R a)
R is a serine esterase conserved domain. Serine esterases,
e.g., tyrpsin, thrombin, chymotrypsin and the like, have a
region that is highly conserved. “Serine esterase conserved
domain” refers to a polypeptide having the amino acid
sequence of one of these conserved regionsoris sufficiently
homologousto one of these conserved regions such that the
thrombin peptide derivative retains NPAR activating ability.
A physiologically functional equivalent of a thrombin
derivative encompasses molecules which differ from throm-
bin derivatives in particulars which do notaffect the function
of the thrombin receptor binding domain or the serine
esterase conserved amino acid sequence. Such particulars
may include,but are not limited to, conservative amino acid
substitutions and modifications, for example, amidation of
the carboxyl terminus, acetylation of the amino terminus,
conjugation of the polypeptide to a physiologically inert
carrier molecule, or sequencealterations in accordance with
the serine esterase conserved sequences.
A thrombin receptor binding domain is defined as a
polypeptide which directly binds to the thrombin receptor
and/or competitively inhibits binding between high-affinity
thrombin receptors and alpha thrombin.
In one embodiment, the serine esterase conserved
sequence has the amino acid sequence of SEQ ID NO: 1
(Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val) or a
C-terminal truncated fragment of a polypeptide having the
amino acid sequence of SEQ ID NO:1.It is understood,
however, that zero, one, two or three amino acids in the
serine esterase conserved sequence can differ from the
corresponding amino acid in SEQ ID-NO:1. Preferably, the
aminoacids in the serine esterase conserved sequence which
differ from the corresponding amino acid in SEQ ID NO:1
are conservative substitutions, and are more preferably
highly conservative substitutions. A “C-terminal truncated
fragment”refers to a fragment remaining after removing an
amino acid or block of amino acids from the C-terminus,
said fragment havingat least six and morepreferablyat least
nine amino acids.
More preferably, the serine esterase conserved sequence
has the amino acid sequence of SEQ ID NO: 2 (Cys-X,-
Gly-Asp-Ser-Gly-Gly-Pro-X,-Val; X, is Glu or Gln and X,
is Phe, Met, Leu, His or Val) or a C-terminal truncated
fragment thereof having at least six amino acids, preferably
at least nine amino acids.
In a preferred embodiment, the thrombin peptide deriva-
tive comprises a serine esterase conserved sequence and a
polypeptide having a more specific thrombin amino acid
sequence Arg-Gly-Asp-Ala (SEQ ID NO: 3). One example
of a thrombin peptide derivative of this type comprises
Arg-Gly-Asp-Ala-Cys-X, -Gly-Asp-Ser-Gly-Gly-Pro-X,-
Val (SEQ ID NO:4). X, and X, are as defined above. When
the thrombin peptide derivative comprises SEQ ID NO:4,it
preferably has the amino acid sequence of SEQ ID NO: 5
(Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-
Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val) or an
N-terminal truncated fragment thereof, provided that zero,
one, two or three amino acids at positions 1-9 in the
thrombin peptide derivative differ from the amino acid at the
corresponding position of SEQ ID NO:5. Preferably, the
aminoacids in the thrombin peptide derivative which differ
from the corresponding amino acid in SEQ ID NO:5 are
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conservative substitutions, and are more preferably highly
conservative susbstitutions. An “N-terminal truncated frag-
ment” refers to a fragment remaining after removing an
amino acid or block of amino acids from the N-terminus,
preferably a block of no more than six amino acids, more
preferably a block of no more than three amino acids.
TP508is an example of a thrombin peptide derivative and
has the amino acid sequence of SEQ ID NO:5. A physi-
ologically functional equivalent of SEQ ID NO:5 is SEQ ID
NO:6 which has the identical amino acid sequence of SEQ
ID NO:5 and also contains a C-terminal amide.
A “conservative substitution” is the replacement of an
amino acid with another amino acid that has the same net
electronic charge and approximately the same size and
shape. Amino acids with aliphatic or substituted aliphatic
amino acid side chains have approximately the same size
whenthe total number carbon and heteroatoms intheir side
chains differs by no more than about four. They have
approximately the same shape when the numberof branches
in the their side chains differs by no more than one. Amino
acids with phenyl or substituted phenyl groups in their side
chains are considered to have about the samesize and shape.
Listed below are five groups of amino acids. Replacing an
amino acid in a polypeptide with another amino acid from
the same group results in a conservative substitution:
Group I: glycine, alanine, valine, leucine, isoleucine,
serine, threonine, cysteine, and non-naturally occurring
amino acids with C1—C4 aliphatic or C1-C4 hydroxyl
substituted aliphatic side chains (straight chained or
monobranched).
Group II: glutamic acid, aspartic acid and non-naturally
occurring amino acids with carboxylic acid substituted
C1-C4 aliphatic side chains (unbranched or one branch
point).
Group III: lysine, omithine, arginine and non-naturally
occurring amino acids with amine or guanidino substi-
tuted C1—C4 aliphatic side chains (unbranched or one
branch point).
Group IV: glutamine, asparagine and non-naturally occur-
ring amino acids with amide substituted C1-C4 ali-
phatic side chains (unbranched or one branch point).
Group V: phenylalanine, phenylglycine, tyrosine and
tryptophan.
A“highly conservative substitution”is the replacement of
an amino acid with another amino acid that has the same
functional group in the side chain and nearly the same size
and shape. Amino acids with aliphatic or substituted ali-
phatic amino acid side chains have nearly the same size
whenthe total number carbon and heteroatoms intheir side
chains differs by no more than two. They have nearly the
same shape when they have the same numberof branchesin
the their side chains. Example of highly conservative sub-
stitutions include valine for leucine, threonine for serine,
aspartic acid for glutamic acid and phenylglycine for phe-
nylalanine. Examples of substitutions which are not highly
conservative include alanine for valine, alanine for serine
and aspartic acid for serine.
Other NPAR agonists include small organic molecules
which bind and activate NPAR. Agonists of this type can be
conveniently identified with high through-put screening,
e.g., with assays that assess the ability of molecules to
stimulate cell proliferation when addedto fibroblasts in the
presence of submitogenic concentrations of thrombin or
molecules that activate protein kinase C or with assays that
assess the ability of these molecules to compete with 1*°I-














in Glennet al., supra, U.S. Pat. Nos. 5,352,664 and 5,500,
412. The entire teachings for Glenn et al., and U.S. Pat. Nos.
5,352,664 and 5,500,412 are incorporated herein by refer-
ence.
The term “NPAR agonist” also includes compounds and
combinations of compounds known to activate NPAR.
Examples are disclosed in U.S. Pat. Nos. 5,352,664 and
5,500,412 and include thrombin and DIP-alpha-thrombin.
NPAR agonists used in the method of the present inven-
tion are typically administered as one component in a
pharmaceutical composition to the site in need ofcartilage
growth, repair or regeneration. Administering to the site in
need of treatment means that the pharmaceutical composi-
tion containing the NPAR agonist is administered in suffi-
cient proximity to the site in need of treatment so that
cartilage growth or cartilage regeneration occurs at the site
(e.g., a greater amountof cartilage growth or better quality
of cartilage growth in the presence of the NPAR agonist than
in its absence).
In one meansof administration, the pharmaceutical com-
position is a solution comprising the NPAR agonist and a
suitable carrier. The solution is applied directly to or in near
proximity to the site in need of treatment. Administration of
the solution can be conveniently accomplished, for example,
intraarticularly by syringe, in close proximity to the dam-
aged tissue by syringe or through a surgical opening. Stan-
dard pharmaceutical formulation techniques may be
employed such as those described in Remington’s Pharma-
ceutical Sciences, Mack Publishing Company, Easton, Pa.
Suitable pharmaceutical carriers for include, for example,
physiological saline, bacteriostatic saline (saline containing
about 0.9% mg/ml benzyl alcohol), phosphate-buffered
saline, Hank’s solution, Ringer’s-lactate and the like.
In another means of administration, the pharmaceutical
composition comprises the NPAR agonist and an implant-
able biocompatible carrier. A biocompatible carrier should
be non-toxic, non-inflammatory, non-immunogenic and
devoid of other undesired reactions at the implantationsite.
Suitable carriers also provide for release of the active
ingredient and preferably for a slow, sustained release over
time at the implantation site.
A numberof synthetic biodegradable polymers can serve
as carriers with sustained release characteristics. Examples
of these polymers include poly a-hydroxy esters such as
polylactic acid/polyglycolic acid copolymers and polyanhy-
drides.
Polylactic acid/polyglycolic acid (PLGA) homo and
copolymers are well knownin the art as sustained release
vehicles. The rate of release can be adjusted by the skilled
artisan by variation of polylactic acid to polyglycolic acid
ratio and the molecular weight of the polymer (see
Anderson, et al., Adv. Drug Deliv. Rev. 28:5 (1997), the
entire teachings of which are incorporated herein by
reference). The incorporation of poly(ethylene glycol) into
the polymer blend allows further attenuation of the release
profile of the active ingredient (see Cleek et al., J. Control
Release 48:259 (1997), the entire teachings of which are
incorporated herein by reference). Suitable implantable
PLGA polymers for use as carriers for cartilage growth
factors are described in U.S. Pat. Nos. 6,013,853, 5,607,474
and 5,876,452, the entire teachings of which are incorpo-
rated herein by reference.
Polyanhydrides, shown in Structural Formula (II), have
well defined degradation and release characteristics that can
be controlled by including varying amounts of hydrophobic
or hydrophilic monomers such as sebacic acid and 1,3-bis
(p-carboxyphenoxy)propane (see Leong et al., J. Biomed.
US 6,855,687 B2
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Mater. Res. 19:941 (1985),the entire teachings of which are
incorporated herein by reference). To improve mechanical
strength, anhydrides are often copolymerized with imides to
form polyanhydride-co-imides. Examples of polyanhydride-
co-imides that are suitable for orthopaedic applications are
poly(trimellitylimido-glycine-co-1,6-bis(carboxyphenoxy)






The pharmaceutical compositions can be shaped as
desired in anticipation of surgery or shaped by the physician
or technician during surgery. It is preferred to shape the
matrix to span a tissue defect and to take the desired form of
the newtissue.In the case of cartilage repair of large defects,
it is desirable to use dimensions that span the defect. After
implantation, the material is slowly absorbed by the body
and is replaced by cartilage in the shape of or very nearly the
shape of the implant.
In one aspect, the carrier is a porous matrix into which
progenitor cells may migrate. Cells can often attach to such
porous matrices, which can then serve as a scaffolding for
tissue growth and thereby accelerate the rate of bone growth.
Chondrocytes can be applied to such matrices prior to
implant to further accelerate healing. Collagen or a collagen
gel is an example of a suitable porous matrix.
In another aspect, the carrier is a viscous solution or gel
that is injectable intraarticuarly or at the site in need of
treatment. Hyaluronic acid is an example of a carrier of this
type. Hyaluronic acid products are commercially available
and include ORTHOVISCdeveloped by Anika, SYNVISC,
developed by Biomatrix, HYALGAN,developed by Fidia
and ARTZ, developed by Seikagaku. Pluronic gel is another
example of this type of carrier. Pluronic gels are nontxoic
block copolymers of ethylene oxide and propylene oxide.
They exhibit thermosetting properties that allow them to
exist as viscous liquids at room temperatures, but as gels at
body temperatures. Injectable compositions can be applied
directly to the site in need of treatment without the need for
invasive surgery. Polymers of poly(ethylene oxide) and
copolymers of ethylene and propylene oxide are also suit-
able as injectable matrices (see Cao et al, J. Biomater. Sci
9:475 (1998) and Simset al., Plast ReconstrSurg. 98:843
(196), the entire teachings of which are incorporated herein
by reference).
A “therapeutically effective amount” is the quantity of
NPAR agonist (or chondrocytes) which results in greater
cartilage growth or repair in the presence of the NPAR
agonist than in its absence. Alternatively or addition, a
“therapeutically effective amount” is the quantity of NPAR
agonist (or chondrocytes) which results in alleviation of the
pain and/or lack of function associated with the cartilage
damage. Typically, the agonist (or chondrocytes) is admin-
istered for a sufficient period of time to achieve the desired
therapeutic or effect. The amount administered will depend
on the amountof cartilage growth thatis desired, the health,
size, weight, age and sex of the subject and the release
characteristics of the pharmaceutical formulation. Typically,
between about 0.1 wg per day and about 1 mg per day of
NPAR agonist (preferably between about 5 wg per day and
about 100 ug per day) is administered by continuous release















A “subject” is preferably a human, but can also be an
animal in need of treatment, e.g., companion animals (e.g.,
dogs, cats, and the like), farm animals (e.g., cows, pigs,
horses and the like) and laboratory animals (e.g., rats, mice,
guinea pigs and thelike).
NPAR agonists can be used to accelerate the growth or to
maintain the functionality of isolated chondrocytes. In one
embodiment, NPAR agonists can be addedto tissue culture
medium to stimulate proliferation and provide for more
rapid proliferation and/or to prevent apoptotic death or
senescence of cells often encountered when primary cell
isolates are place in culture. In another embodiment, because
the NPAR agonists appear to stimulate matrix production,
such NPAR agonists could be used to maintain the differ-
entiated functionality of chondrocytes in culture. NPAR
agonists can be used alone in standard defined tissue culture
medium or as a supplementto tissue culture medium con-
taining serum or other growth factor to provide additive or
synergistic effects on the in vitro production or maintenance
of chondrocytes. A sufficient quantity of the NPAR agonist
is added to the culture to provide more rapid growth or to
maintain greater functionality of the chondrocytes than in
the absence of the agonist, ie., a “stimulatory amount”.
Typically, between about 0.1 “g/ml and about 100 ug/ml of
NPAR agonist is used.
Chondrocytes cultured in the presence of an NPAR ago-
nists can also be used to treat cartilage damage by admin-
istering a therapeutically effective amount of the chondro-
cytes to the site in need of treatment. With respect to
chondrocytes, “therapeutically effective” also means which
results in greater cartilage growth or repair with the treat-
mentthan in its absence. The administration of chondrocytes
to treat cartilage damage is described in U.S. Pat. No.
4,846,835, the entire teachings of which are incorporated
herein by reference.
Thrombin peptide derivatives can be synthesized by solid
phase peptide synthesis (e.g., BOC or FMOC) method, by
solution phase synthesis, or by other suitable techniques
including combinations of the foregoing methods. The BOC
and FMOC methods, whichare established and widely used,
are described in Merrifield, J. Am. Chem. Soc. 88:2149
(1963); Meienhofer, Hormonal Proteins and Peptides, C. H.
Li, Ed., Academic Press, 1983, pp. 48-267; and Barany and
Merrifield, in The Peptides, E. Gross and J. Meienhofer,
Eds., Academic Press, New York, 1980, pp. 3-285. Methods
of solid phase peptide synthesis are described in Merrifield,
R. B., Science, 232: 341 (1986); Carpino, L. A. and Han, G.
Y., J. Org. Chem., 37: 3404 (1972); and Gauspohl,H.etal.,
Synthesis, 5: 315 (1992)). The teachingsofthese six articles
are incorporated herein by reference in their entirety.
The invention is illustrated by the following examples
which are not intended to be limiting in any way.
EXEMPLIFICATION
Details of Experiments
Chondrocytes are the primarycell type found in cartilage.
In cartilage these cells are normally quiescent, or non-
proliferative, and have relatively low metabolic rates. Fol-
lowing injury to cartilage these cells do not readily partici-
pate in the repair process. Due to the avascular nature of
cartilage, these cells presumably would not see thrombin as
an initiator of the repair process. The following examples
demonstrate that chondrocytes have thrombin receptors and
that compounds that activate NPAR stimulate chondrocyte
proliferation and synthesis of matrix proteoglycans.
EXAMPLE1
Thrombin Binding to Rat Chondrocytes
Primary cultures of rat articular chondrocytes were iso-
lated and prepared for in vitro analysis using established
US 6,855,687 B2
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methods (see Kuettner, K E., et.al., J. Cell Biology 93:
743-750, 1982). Briefly, cartilage pieces were dissected
from the shoulder of rats and the pieces were digested with
trypsin for one hour and with collagenase for three hours in
tissue culture medium (DMEM)at 37 C. with stirring. The
cells were plated in flasks at high density (50,000 cells/cm
sq.) and were culture in DMEM containing antibiotics an
ascorbic acid at 37° C. in an atmosphere of 5% CO.
Thespecific binding of ‘*°I thrombin to chondrocytes was
carried out using established thrombin receptor binding
assays as disclosed in US. Pat. No. 5,352,664 and Camey,
D H and Cunningham, DD, Cell 15:1341-1349, 1978.
Briefly, highly purified human thrombin was iodinated and
added to cultures of chondrocytes with or without unlabeled
thrombin to correct for nonspecific binding. By incubating
cells with different concentrations of labeled thrombin and
measuring the amount of thrombin boundto cells and the
amount of free thrombin in the medium it is possible to
estimate the numberof receptors per cell and the affinity of
thrombin for that bindingsite.
Scatchard analysis of the labeled thrombin binding from
three separate experiments suggest that rat chondrocytes
express an average of 3000 very high affinity bindingsites
(100 pM affinity) and 230,000 high affinity sites (27 nM).
EXAMPLE 2A
NPAR Agonist Stimulation of Bovine Chondrocyte
Proliferation
Primary cultures of bovine chondrocytes were prepared
using the procedure described for rat chondrocytes in
Example 1. The cultures were subcultured into 24 well
plastic dishes at a low density and placed in 1% serum.
Addition of the NPAR agonist TP508 to these cultures at
concentrations of 1.0 or 10 ug/mlbyitself did not stimulate
cell proliferation. In contrast, addition of these concentra-
tions of TP508 together with a small amount of thrombin
co-mitogen, resulted in a small, but significant (p<0.05)
increase in cell number relative to that seen in thrombin
alone after three days in culture.
EXAMPLE 2B
NPAR Agonist Stimulation of Bovine Chondrocyte
Proteoglycan Synthesis
To determinethe effect of NPAR agonists on proteoglycan
synthesis, bovine chondrocytes were seeded into 96 well
plates at a density of 2x105 cells per well and cultured in
DMEM with 10% fetal calf serum. After establishment of
these multi-layer cultures, the medium wasreplaced daily
with DMEM containing 1% serum with indicated concen-
trations of TP508 from 1 to 100 wg per ml (Table 1). After
6 days in culture with daily changes of culture medium with
or without TP508, *°S sulfate was added to the medium and
incubation continued for an additional 24 hours. As shown
in Table 1, treatment with high concentrations of TP508 (100
ug per ml) increased *°S sulfate incorporation relative to




















Treatment 1% Serum Std. Dev of Mean
Control 4975 3552
TP508 (1 wg/ml) 4701 2692
TP508 (10 ug/ml) 6960 3265
TP508 (100 ug/ml) 81946 13783
EXAMPLE 3A
NPAR Agonist Stimulation of Proliferation
Synthesis in Cultured Rat Articular Chondrocytes
Ratarticular chondrocytes wereisolated from slices of rat
articular shouldercartilage utilizing trypsin and collagenase
digestions as described in Example 1. Preparations of chon-
drocyte “3-dimensional” alginate bead cultures were estab-
lished using established techniques as described by Guoet.
al., (Conn.Tiss. Res. 19:277-297, 1998). Following removal
of cells from tissue culture flasks with trypsin, the cells were
suspended in an alginate gel (1.2% w/v) and slowly
expressed through a 22 gauge needle in a dropwise fashion
into 102 mM CaCl,. As the drops contact the CaCl, there is
a nearly instantaneous polymerization of the alginate to
create a gel bead. The beads were then washedthree times
in DMEMculture medium andtransferred to 35 mm dishes
and maintained in culture at 37 C. in a 5% CO2 atmosphere
by feeding with culture medium every two days.
The effect of NPAR agonist TP508 on chondrocyte cell
proliferation after three days in 3-dimensional alginate cul-
ture was determined by removing beads from 35 mm dishes,
washing them with 0.9% saline, and dissolving the alginate
beads by adding 1 ml of 55 mM sodium citrate, 0.15 M NaCl
at 37° C. for 10 minutes. Cell number was determined by
diluting the 1 ml of dissolved beads 1:10 with phosphate
buffered saline (PBS) and counting the cells with a Z-series
Coulter Counter. As shown in Table 2, TP508 by itself




Effect of the NPAR agonist TP508 on Proliferation of Rat
Chondrocytes in 3-D Bead Culture.
 
Cells/bead Std. % Increase
Treatment After 3 days dev over Control
Control 6238 688
TP508 30 nM 7463 167 19.7
TP508 300 nM 8882 148 42.4
TP508 3 4M 8866 4 42.1
TP508 30 uM 7172 258 24.6
EXAMPLE 3B
NPAR Agonist Stimulation of Proteoglycan
Synthesis in Cultured Rat Articular Chondrocytes
To determine the effects of the NPAR agonist TP508 on
proteoglycan synthesis, 3-dimensional alginate cultures
were prepared as described above and assayed for incorpo-
ration of [>°S]-sulfate. Bead cultures were exposedto indi-
cated concentrations of TP508 as well as [*°S]-sulfate (20
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uCi/ml) and with daily medium changes and were harvested
on days 7 for [?°S]-sulfate incorporation. At each time point
5-10 beads were removed, washed 3x with 0.9% saline,
dissolved by adding 0.5 ml of 55 mM sodium citrate, 0.15
M NaCl at 37 C. for 10 minutes as described above, and
counted in a liquid scintillation counter. [*°S]-sulfate incor-
poration was normalized in each sample for numberofbeads
added. As shown in Table 3, TP508 treatment alone at a
concentration of 300 nM (about 0.7 ug per ml), stimulated
[°°S]-sulfate incorporation about 50% over controls. There
wasalso a large stimulation by 30 uM TP508 (about 70 ug
per ml), however, there wasa largerelative standard devia-




Effect of the NPAR agonist TP508 on [°°S]-sulfate incorporation into
proteoglycans.
Std. % Increase
Treatment CPM/bead dev over Control
Control 665 24
TP508 30 nM 829 87 24.7
TP508 300 nM 1008 29 51.6
TP508 3 uM 827 9 24.1
TP508 30 «uM 1153 519 73.3
EXAMPLE4
Preparation of Polylactic Acid/Polyglycolic Acid
Copolymer Microspheres of TP508
A double emulsion technique was used to prepare micro-
spheres of polylactic acid/polyglycolic acid copolymer
(PLGA)containing TP508. Briefly, the matrix components
were dissolved in methylene chloride and TP508 was dis-
solved in water. The two were gradually mixed together
while vortexing to form a water-in-oil (W/O) emulsion.
Polyvinyl alcohol (0.3% in water) was added to the emulsion
with further vortexing to form the second emulsion (O/W),
thereby forming a double emulsion: an O/W emulsion
comprised of PLGA droplets, and within those droplets, a
second disperse phase consisting of TP508 in water. Upon
phase separation, the PLGA droplets formed discrete micro-
spheres containing cavities holding TP508. To cause phase
separation of the microspheres, a 2% isopropyl alcohol
solution was added. The particles were collected by
centrifugation, and then lyophilized to remove residual
moisture. The composition of the matrix was varied to form
microspheres with different release kinetics (Table 4).
TABLE 4
 
Composition of different microsphere formulations
Polymer % % polyethylene
Formulation PLA:PGA M. Wt. TP508 glycol
A 50:50 46,700 5 0)
B 50:50 7,200 5 0)
Cc 50:50 46,700 5 5
D 50:50 46,700 5 0)
E 75:25 120,000 5 0)
 
The mean diameter of the microspheres was measured in
a Coulter counter and the drug entrapment efficiency was
measured by spectrophotometric assay at 276 nm following
dissolution of a weighed sample of microspheres in meth-

















Formulation diameter and drug entrapment efficiency







To measure TP508 release from the different PLGA
matrices, 20 mg of microspheres were placed in 1.0 ml of
PBS contained in 1.5 ml polypropylene microcentrifuge
tubes. Tubes were incubated at 37° C. and shaken at 60 rpm.
Atvarious times, the tubes were centrifuged and the super-
natant containing released TP508 was removed and frozen
for subsequent analysis. Fresh PBS wasaddedto the micro-
spheres and incubation was continued. TP508 in the super-
natant was measured by absorbance at 276 nm. For each
formulation, quadruplicate release determinations were per-
formed. Formulations B and D showed nodetectable drug
release during 28 days of incubation at 37° C. The remaining
formulations all released detectable amounts of TP508,
although in all cases the amountof drug released fell below
detectable limits (<1 “g/mg matrix/day) within 3-4 days.
Formulations A and C showedthe greatest release of TP508,
releasing 60-80% of the entrapped drug over 3-4 days.
Formulation C showed the fastest release kinetics and was
chosen for testing in the rabbit cartilage defect model
described in Example 5.
EXAMPLE5
The NPAR Agonist TP508 Stimulates Cartilage
Growth in Rabbit Models
Young, male New Zealand rabbits (2-3 kilograms) (n=15)
were anesthetized and given bilateral, medial longitudinal
parapatellar arthrotomies. The skin, subcutaneoustissue and
joint capsule were incised, using electrocautery to minimize
bleeding. The joint surface was exposed by lateral disloca-
tion of the patella. A 3-mm diameter, 1-2-mm deep full-
thickness defect was made in the trochlear groove of the
femur using a surgical drill and pointed stainless steel drill
bit. The aim was to extend the defect into the subchondral
plate without piercing the subchondral bone.
The rabbits were divided into three groups. For each
rabbit, both rightandleft trochlear groove defects werefilled
with the same treatment. For this study, TP508 was formu-
lated into PLGAcontrolled release microspheres, prepared
as described in Example 4 (Formulation C). The micro-
spheres were mixed with sufficient Pluronic F68 gel (5%
w/v) to bind the spheres together into a paste-like consis-
tency that could easily be packed into the defect. The control
group received PLGA microspheres without TP508 in both
defects. The treated groups received microspheres contain-
ing either 10 or 50 mg of TP508/defect. One rabbit from
each group was sacrificed at 4 weeks, 2 from each group
were sacrificed at 6 weeks and the remaining animals were
sacrificed at 9 weeks. Samples were fixed and processed for
histological analysis.
Atthe timeofsacrifice, there appeared to be considerable
fibrous granulation tissue and no evidence of white
cartilage-like material in the control defects. In contrast, the
defect had a nearly uniform, dense, white material filling in
the defects from the 10 yg treated group and 50 wg group. By
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6 weeks post-surgery, the macroscopic differences between
treated and control defects were not so pronounced.
Histology of the four week samples showed that indeed
the control defects were filled with what appeared to repre-
sent early granulation tissue including inflammatory and
fibroblastic cells. In contrast, the 10 and 50 microgram
treated defects appeared to have a large number of chon-
drocytes and early signs of cartilage formation. This effect
was seen more dramatically at week six. Controls had a
small amount of connective tissue, yet little evidence of
cartilage repair. In contrast, in both the 10 wg and 50 yng
treated defects, there appeared to be good integration with
hyaline cartilage forming at the top of the defect and
extensive subchondral bone repair.
Nine-week TP508 treated defects exhibited a predomi-
nantly hyaline matrix with evidence of significant aggrecan
content as shownbypositive safranin-O staining. In most
instances there was no difference in aggrecan content
between the repair site and native tissue. Histological results
were quantitatively assessed using a grading system adapted
by Freed, et al., J. Biomed. Materials Res. 28:891-899
(1944) from the scheme of O’Driscoll, et al., J. Bone Joint
Surg. 126:1448-1452 (2000) with a maximum score of 25
for normalarticular cartilage. Experimental TP508 treated
defects scored mean averagesthat were significantly higher








Histology Scoring For Articular Defect Study
Milligrams of TP508 Repair Score + SE
0 94+ 1.6
10 18.6 + 1.4
50 19.8 + 1.0
Peptide treated defects repaired with smooth articular
surfaces and were typically well bonded at the junction
between repair and native tissue. The quality of control
repair tissue was characterized as mostly fibrocartilage with
poor quality joint surfaces. Integration at the junction
between repair and native tissue was usually poor. Overall,
the quality of cartilage repaired with TP508 was signifi-
cantly enhanced over control non-treated defects. This
improved quality of repair tissue should lead to more
durable and functional restoration of joint biomechanics and
reduction in the incidence of osteoarthritis in patients suf-
fering from traumatic cartilage injuries.
While this invention has been particularly shown and
described with references to preferred embodimentsthereof,
it will be understood by those skilled in the art that various
changes in form and details may be made therein without

















Cys Glu Gly Asp Ser Gly Gly Pro Phe Val
OTHER INFORMATION: peptide fragment of thrombin
1 5 10
<210> SEQ ID NO 2
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:








<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 2
Cys Xaa Gly Asp Ser Gly Gly Pro Xaa Val
1 5 10
<210> SEQ ID NO 3
<211> LENGTH: 4
<212> TYPE: PRT






<223> OTHER INFORMATION: peptide fragment of thrombin
<400> SEQUENCE: 3
Arg Gly Asp Ala
1
<210> SEQ ID NO 4
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:








<223> OTHER INFORMATION: Xaa = Phe, Met, Leu, His or Val
<400> SEQUENCE: 4
Arg Gly Asp Ala Cys Xaa Gly Asp Ser Gly Gly Pro Xaa Val
1 5 10
<210> SEQ ID NO 5
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: peptide fragment of thrombin
<400> SEQUENCE: 5
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 6
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:




<223> OTHER INFORMATION: Amidation at C-terminus
<400> SEQUENCE: 6
Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10 15
Asp Ser Gly Gly Pro Phe Val
20
<210> SEQ ID NO 7
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:










Ala Gly Tyr Lys Pro Asp Glu Gly Lys Arg Gly Asp Ala Cys Glu Gly
1 5 10




1. Amethodof stimulating cartilage growth at an arthritic
joint in a subject, said method comprising the step of
administering to the site a therapeutically effective amount
of the peptide Ala-Gly-Try-Lys-Pro-Asp-Glu-Gly-Lys-Arg-
Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val-
NH, (SEQ ID NO:7).
2. A method of stimulating cartilage growth in a subject
at a site being treated for cartilage loss, said method com-
prising the step of administering to the site a therapeutically
effective amount of the peptide Ala-Gly-Try-Lys-Pro-Asp-
Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-
Gly-Pro-Phe-Val-NH, (SEQ ID NO:7).
3. A method of stimulating cartilage growth in a subject
at a site being treated for cartilage loss due to traumatic
15
20
injury, said method comprising the step of administering to




4. A method of stimulating cartilage growth or repair at a
site in a subject in need of such growthor repair, said method
comprising the step of administering to the site a therapeu-
tically effective amountof the peptide Ala-Gly-Try-Lys-Pro-
Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-
Gly-Gly-Pro-Phe-Val-NH, (SEQ ID NO:7).
